Diffuse large B-cell lymphoma trials in Germany

In Germany 14 Also abroad 346

14 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Where
Berlin, Cologne, Magdeburg
Age
18 years and over
People
130 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06806033 · EU 2024-516791-15-00
Phase 3Taking people
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Where
Berlin, Dresden, Essen, Frankfurt am Main, Homburg, Kiel, Mainz, Mutlangen, Stuttgart
Age
18 years and over
People
904 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00
Phase 1Taking people
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Where
Cologne, Essen, Frankfurt Am Main
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00
Phase 2Taking people
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Where
Aachen, Bonn, Chemnitz, Erlangen, Essen, Frankfurt am Main, Goettingen, Hanover, Jena, Kassel, Koblenz, Luebeck, Magdeburg, Muenster, Munich, Neubrandenburg, Oldenburg, Stuttgart, Tuebingen, Ulm, Wuerzburg, Wuppertal, Zwickau
Age
18 years and over
People
594 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06890884 · EU 2024-515526-89-00
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Berlin, Cologne, Giessen, Muenster, Tuebingen
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 3Taking people
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a randomized phase III trial - PRIMA-CNS
Where
Aachen, Augsburg, Berlin, Bielefeld, Bremen, Brunswick, Chemnitz, Cologne, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Goettingen, Halle (Saale), Hamburg, Homburg, Karlsruhe, Kiel, Koblenz, Leipzig, Luebeck, Magdeburg, Mainz, Muenster, Munich, Nuremberg, Oldenburg, Regensburg, Rostock, Siegen, Stuttgart, Trier, Tuebingen, Ulm, Villingen-Schwenningen
Age
65 years and over
People
260 worldwide
Run by
Medical Center - University Of Freiburg
See details and how to join2024-512320-11-00 · EU 2024-512320-11-00
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Cologne, Dresden, Leipzig, Lübeck, Mainz, München, Ulm
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
Phase 1Taking people
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
Where
Dresden
Age
18 years and over
People
16
Run by
Technische Universität Dresden
See details and how to joinNCT05836896 · EU 2022-502831-20-00
Phase 2Taking people
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Where
Aachen, Augsburg, Berlin, Bielefeld, Chemnitz, Dortmund, Duesseldorf, Erlangen, Essen, Frankfurt Am Main, Freiburg im Breisgau, Goettingen, Greifswald, Halle Saale, Hamburg, Hamm, Heidelberg, Homburg, Jena, Karlsruhe, Kiel, Luebeck, Mainz, Marburg, Minden, Muenster, Munich, Mutlangen, Offenburg, Oldenburg, Paderborn, Regensburg, Stuttgart, Ulm
Age
18 years and over
People
120 worldwide
Run by
Universität Münster
See details and how to joinNCT07197307 · EU 2023-509861-19-01
No phaseTaking people
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Where
Freiburg im Breisgau
Age
18 years and over
People
2,950
Run by
iOMEDICO AG
See details and how to joinNCT06043011
Phase 3Taking people
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
Where
Aachen, Aalen, Amberg, Augsburg, Bamberg, Bayreuth, Berlin, Bonn, Bremen, Chemnitz, Cologne, Dresden, Eberswalde, Essen, Esslingen am Neckar, Frankfurt am Main, Frankfurt (Oder), Giessen, Greifswald, Halle Saale, Hamburg, Heilbronn, Hildesheim, Homburg, Kaiserslautern, Karlsruhe, Lübeck, Magdeburg, Minden, Muenster, Munich, Neuss, Nuremberg, Paderborn, Rheine, Rostock, Saarbruecken, Saarlouis, Siegen, Stuttgart, Traunstein, Trier, Ulm, Wolfsburg, Wuppertal
Age
61 years and over
People
330 worldwide
Run by
Universität des Saarlandes
See details and how to joinNCT05820841 · EU 2022-501187-18-00
Phase 2Taking people
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Where
Augsburg, Berlin, Bochum, Cologne, Erlangen, Essen, Hamburg, Heidelberg, Leipzig, Muenster, Munich, Regensburg, Tuebingen
Age
18 years to 70 years
People
213 worldwide
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT04844866 · EU 2023-506270-13-00
Phase 1/2Taking people
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
Where
Heidelberg
Age
3 years and over
People
68
Run by
University Hospital Heidelberg
See details and how to joinNCT03676504 · EU 2024-516832-82-00
No phaseTaking people
Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)
Where
Göttingen
Age
18 years to 85 years
People
500
Run by
University Medical Center Goettingen
See details and how to joinNCT06526065